Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Published:2009-07 Issue:4 Volume:10 Page:252-256
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Patel Jyoti D.,Bonomi Philip,Socinski Mark A.,Govindan Ramaswamy,Hong Shengyan,Obasaju Coleman,Pennella Eduardo J.,Girvan Allicia C.,Guba Susan C.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. Optimal duration of chemotherapy in advanced nonsmall cell lung cancer;Lustberg;Curr Treat Options Oncol,2007

2. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs. (review);Boulikas;Oncol Rep,2004

3. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003;Pfister;J Clin Oncol,2004

4. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up;D'Addario;Ann Oncol,2008

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139;Clinical Lung Cancer;2022-11

2. Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab;Frontiers in Oncology;2022-05-18

3. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies;OncoTargets and Therapy;2021-05

4. Marginal structural models and other analyses allow multiple estimates of treatment effects in randomized clinical trials: Meta-epidemiological analysis;Journal of Clinical Epidemiology;2019-03

5. The Role of Anti-Angiogenic Agents (VEGF);Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners;2019